KIN-8741

**KIN-8741** is a highly selective **Type IIb c-Met kinase inhibitor** developed by Kinnate Biopharma for the treatment of **c-Met-driven cancers**, particularly **non-small cell lung cancer (NSCLC)** and other **solid tumors**. It exhibits broad potency against **acquired resistance mutations** in c-Met (hepatocyte growth factor receptor, HGFR/MET), addressing limitations of existing inhibitors where up to 35% of patients develop on-target resistance. The small molecule (molecular formula C26H23F2N3O6, CAS 2941104-53-4) demonstrates **antitumor activity** in MET-amplified models and possesses quality drug-like properties, with plans for an IND filing in Q4 2023 and clinical entry in H1 2024 pending FDA clearance.[1][2][3][5][7][9]